“Managing the starting dose of our first participant candidate vaccine only marks the beginning of this Phase 1 clinical trial, but it also represents a significant step in the overall fight against COVID-19,” said Mei Mei Hu, CO-CEO of COVAXX.
The Open Phase 1 trial is designed to evaluate the safety, tolerability and immunogenicity of UB-612, a coVID-19 candidate multitope peptide vaccine based on a commercially proven platform that enables cost-effective vaccine production at Ladder. The design of the vaccine parts provides the additional advantages of existing distribution channels and bloodless chain garage, as it requires no more infrastructure, such as freezers at -80 C or liquid nitrogen tanks to buy fabrics at temperatures above -80 C